<DOC>
	<DOCNO>NCT01812486</DOCNO>
	<brief_summary>A randomized clinical trial initiate investigate whether reduction dose elective nodal sit swallow apparatus deliver IMRT would result reduction acute late side effect without compromise tumor control .</brief_summary>
	<brief_title>Dose De-escalation Elective Nodal Sites Head Neck Cancer</brief_title>
	<detailed_description>1 . Study hypothesis Dose de-escalation elective nodal sit off-target region swallow apparatus deliver IMRT reduce overall rate late dysphagia neck fibrosis compare standard dose elective nodal site . 2 . Primary endpoint To estimate difference overall rate late dysphagia neck fibrosis 1 year end radiotherapy patient receive dose de-escalation elective nodal sit off-target region swallow apparatus apply IMRT . 3 . Secondary endpoint Local , regional distant control Recurrence site recurrence Overall , disease-free disease-specific survival Acute toxicity Quality life</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>oral cavity , oropharynx , hypopharynx larynx SCC Histolocervical lymph node metastases unknown primary cancer Primary unresectable tumor and/or patient refuse surgery Stage T24 ; T34 N0 Tany N13 laryngeal cancer Karnofsky performance status ≥70 % Age ≥ 18 year old Treatment combine brachytherapy Prior irradiation head neck region History prior malignancy , except cure nonmelanoma skin cancer , curatively treat insitu carcinoma cervix cancer curatively treat evidence disease least 5 year Distant metastasis Pregnant lactate woman Patient unlikely comply protocol , i.e . uncooperative attitude , inability return followup visit , unlikely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>